$0.2528
0.002801.12%
Pre-Market: 7:59 PM EDT
Comments
Loading...
Adaptimmune Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:ADAP | Benzinga
Adaptimmune Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
May 14
EPS Estimate
$-0.150
Quarterly Revenue Estimate
$6.30M
Annual Revenue
(as of Dec 31)
(as of Dec 31)
$178.03M
Analyze the earnings history of Adaptimmune Therapeutics using advanced sorting and filters.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ADAP | Adaptimmune Therapeutics | -$0.18 | -$0.15 | — | — | $5.68M | $6.30M | — | — | 05/14/2025 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.24 | -$0.15 | -$0.30 | -100.00% | $231.00K | $8.42M | $3.22M | -61.73% | 03/20/2025 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.18 | -$0.13 | -$0.07 | 46.15% | $7.32M | $11.17M | $40.90M | 266.17% | 11/13/2024 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.12 | -$0.08 | $0.24 | 400.00% | $5.13M | $38.48M | $128.23M | 233.24% | 08/12/2024 | Get Alert |
| ADAP | Adaptimmune Therapeutics | $0.00 | -$0.10 | -$0.18 | -80.00% | $47.60M | $10.73M | $5.68M | -47.08% | 05/15/2024 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.18 | -$0.10 | -$0.24 | -140.00% | $11.03M | $20.47M | $231.00K | -98.87% | 03/06/2024 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.24 | -$0.15 | -$0.18 | -20.00% | $7.01M | $10.28M | $7.32M | -28.80% | 11/08/2023 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.05 | -$0.13 | -$0.12 | 7.69% | $5.54M | $8.78M | $5.13M | -41.57% | 08/09/2023 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.05 | -$0.14 | $0.00 | 100.00% | $3.58M | $4.93M | $47.60M | 865.54% | 05/12/2023 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.04 | -$0.25 | -$0.18 | 28.00% | $1.42M | $4.12M | $11.03M | 167.67% | 03/06/2023 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.30 | -$0.24 | -$0.24 | 0.00% | $1.20M | $4.04M | $7.01M | 73.44% | 11/08/2022 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.24 | -$0.25 | -$0.28 | -12.00% | $3.10M | $6.00M | $5.54M | -7.70% | 08/04/2022 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.04 | -$0.22 | -$0.32 | -45.45% | $434.00K | $3.29M | $3.58M | 8.66% | 05/09/2022 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.24 | $0.14 | -$0.25 | -278.57% | $1.50M | $96.45M | $1.42M | -98.53% | 03/14/2022 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.24 | -$0.26 | -$0.30 | -15.38% | $1.19M | $1.37M | $1.20M | -12.19% | 11/04/2021 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.24 | -$0.24 | -$0.24 | 0.00% | $502.00K | $1.36M | $3.10M | 127.57% | 08/09/2021 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.04 | -$0.25 | -$0.24 | 4.00% | $761.00K | $1.83M | $434.00K | -76.28% | 05/06/2021 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.05 | -$0.23 | -$0.24 | -4.35% | $728.00K | $1.98M | $1.50M | -24.14% | 02/25/2021 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.06 | -$0.25 | -$0.24 | 4.00% | $237.00K | $870.00K | $1.19M | 37.13% | 11/05/2020 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.07 | -$0.23 | -$0.24 | -4.35% | $157.00K | $930.00K | $502.00K | -46.02% | 08/06/2020 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.04 | -$0.25 | -$0.04 | 84.00% | $0.00 | $23.29M | $761.00K | -96.73% | 05/14/2020 | Get Alert |
Adaptimmune Therapeutics (ADAP) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q4 | 2025-03-20 | $-0.30 | $-0.15 | -100.0 % |
| Q3 | 2024-11-13 | $-0.07 | $-0.13 | 46.2 % |
| Q2 | 2024-08-12 | $0.24 | $-0.08 | 400.0 % |
| Q1 | 2024-05-15 | $-0.18 | $-0.10 | -80.0 % |
Adaptimmune Therapeutics (ADAP) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q4 | 2025-03-20 | $3.22M | $8.42M | -61.7 % |
| Q3 | 2024-11-13 | $40.90M | $11.17M | 266.2 % |
| Q2 | 2024-08-12 | $128.23M | $38.48M | 233.2 % |
| Q1 | 2024-05-15 | $5.68M | $10.73M | -47.1 % |
FAQ
When is Adaptimmune Therapeutics (NASDAQ:ADAP) reporting earnings?
Adaptimmune Therapeutics (ADAP) is scheduled to report earnings on May 14, 2025. The last reported earnings were for reported on March 20, 2025 for Q4.
What were the latest earnings per share (EPS) for Adaptimmune Therapeutics (NASDAQ:ADAP)?
The Actual EPS was $-0.30, which missed the estimate of $-0.15.
What were Adaptimmune Therapeutics’s (NASDAQ:ADAP) revenues?
The Actual Revenue was $3.2M, which missed the estimate of $8.4M.
Browse earnings estimates, EPS, and revenue on all stocks.